-

Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

Unique Fourier 80 ‘Multi-Talent’ offers 1H NMR and choice of 15 X-nuclei with just one click

ASILOMAR, Calif.--(BUSINESS WIRE)--At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier 80 ‘Multi-Talent’ system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with dramatically enhanced versatility in benchtop FT-NMR multinuclear analysis.

The Fourier 80 ‘Multi-Talent’ system measures or decouples 1H, and in addition can select one of 15 different X-nuclei to be either observed in X{1H} experiments, or selected X-nuclei can be decoupled for proton observation in 1H{X} experiments. This enables many types of X-nucleus observations, various 2D experiments, and importantly also the exquisitely sensitive inverse 1H observation methods for 13C, 19F or 15N experiments.

Similarly, the Fourier 80 ‘Multi-Talent’ can observe 19F{1H} with proton decoupling for the simplification of 19F spectra, a capability of high interest to pharmaceutical customers studying fluorinated drug candidates. For battery research, the Fourier 80 ‘Multi-Talent’ enables nuclei observations from Li-brine mining, like 7Li, 23Na, and 11B for the formulation of battery electrolytes. Novel electrochemical systems can be explored to advance next generation battery technologies. These unprecedented benchtop capabilities are selectable via software, eliminating the need for NMR probe tuning and matching.

The ‘Multi-Talent’ uses standard 5 mm NMR samples, includes gradient spectroscopy, with options for adjustable sample temperature (AT), or sample changer automation. The user-friendly Fourier 80 interface ensures that novice and experienced users can navigate through measurements effortlessly, streamlining complex tasks and enhancing productivity.

Dr. Agnes Haber, the Fourier 80 Product Manager at Bruker BioSpin, stated: "The Fourier 80 ‘Multi-Talent’ represents a game-changing advancement in benchtop FT-NMR, with next-generation multinuclear capabilities addressing the demand for a versatile system for 1H-NMR, plus an unprecedented choice of fifteen X-nuclei, with ease, and even under automation. We have already successfully installed a dozen Fourier 80 multinuclear systems in customer labs, and we anticipate that this novel system may become the new de facto standard in benchtop multinuclear NMR spectroscopy."

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Investor Contact:
Joe Kostka
Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 373-3531
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Joe Kostka
Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 373-3531
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI)

BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of the Extreme Light Infrastructure – Nuclear Physics (ELI-NP) at the Horia Hulubei National Institute of Physics and Nuclear Engineering (IFIN-HH) in Romania. The total value of these ELI contracts is approximately €35 million (more than USD $40 million), w...

Bruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions

ETTLINGEN, Germany--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced several significant European orders for high-performance magnetic resonance systems from three leading research institutions in France and Germany: In the summer, École Normale Supérieure (ENS-PSL) in Paris, France ordered a novel NMR relaxometry system to be used alongside its recently acquired 900 MHz NMR spectrometer. This unique capability will empower the investigation of the molecular dynamics of protei...

Bruker Announces the Addition of Diagnostics Industry Leader Jack Phillips to its Board of Directors as of January 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has added Jack J. Phillips to serve on its board of directors, effective as of January 1st, 2026. Mr. Phillips is a senior healthcare industry executive with over 30 years of leadership experience in the diagnostics industry. Frank H. Laukien, chairman, president and CEO of Bruker Corporation, stated: “Bruker is delighted to add Jack to our board of directors. His broad and deep diag...
Back to Newsroom